Moderna (MRNA) Payables (2017 - 2026)

Moderna (MRNA) has 10 years of Payables data on file, last reported at $161.0 million in Q1 2026.

• Payables for Q1 2026 came in at $161.0 million, down 28.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $161.0 million (down 28.76% YoY), and the FY2025 annual result was $317.0 million, down 21.73% from the prior year.
• Payables retreated to $161.0 million in Q1 2026 per MRNA's latest filing, from $317.0 million in the prior quarter.
• Over five years, Payables peaked at $520.0 million in Q4 2023 and troughed at $161.0 million in Q1 2026.
• A 5-year average of $311.5 million and a median of $310.0 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2024: Payables soared 2387.5% in 2022, then slumped 52.96% in 2024.
• A 5-year view of Payables shows it stood at $487.0 million in 2022, then grew by 6.78% to $520.0 million in 2023, then retreated by 22.12% to $405.0 million in 2024, then dropped by 21.73% to $317.0 million in 2025, then plunged by 49.21% to $161.0 million in 2026.
• Business Quant data shows MRNA's Payables at $161.0 million in Q1 2026, $317.0 million in Q4 2025, and $267.0 million in Q3 2025.